Ultragenyx’s Sanfilippo approval arrives as pricing details circulate, with the therapy priced at $4 million for Sanfilippo gene therapy treatment, underscoring how ultra-rare approvals can quickly become central to reimbursement and value debates. The approval also renews attention on how gene therapy pricing can shape access while affecting investor expectations around long-term revenue durability. The excerpt also points to broader gene- and cell-therapy developments in the same news flow, including a Roche-reported success in blood cancer and a separate cost-cutting move by a cell therapy maker. Together, the items reinforce that investors are looking at both clinical outcomes and post-approval business models. In addition to price signaling, gene therapy approvals often come with manufacturing complexities and long-tail safety monitoring requirements, which can further affect how payers model risk. For the sector, this package highlights the immediate linkage between FDA actions, launch economics, and how quickly market participants price in commercialization outcomes beyond the trial label.